All In Biotech

Drug Trial Radar · NCT07915219

A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

An Open-label, Roll-over Study Evaluating the Long-term Safety and Efficacy of an Oral Dose of Verducatib q.d. in Patients With Bronchiectasis (AIRTIVITY®-ON)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,500

Planned (sponsor's estimate)

Start

Jan 11, 2027

Primary completion

Jul 31, 2029

Study completion Sep 10, 2029

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is for adults and adolescents who are at least 12 years old and have bronchiectasis. People can participate if they completed a previous study with the study medicine called verducatib. The purpose of this study is to find out how well verducatib is tolerated when people with bronchiectasis take it for a long time. The study also looks at breathing problems, how often lung flare-ups happen, and how quickly lung function changes. This is a roll-over study for participants who completed a previous study with verducatib: AIRTIVITY® (1397-0014) or CLAIRLEAF® (1397-0017). All participants receive verducatib. Participants take verducatib as tablets once a day at home. They may continue their usual treatment for bronchiectasis during the study. Participants can stay in the study for up to 1 year and 9 months. Treatment with verducatib can continue for up to 1 year and 6 months. About 6 study visits are done at the study site and about 4 are done by phone. At all visits, the doctors check participants' health and collect information on any health problems that occur during the study. The doctors also look at lung flare-ups and measure lung function over time.

Conditions

  • Bronchiectasis

Interventions

  • verducatibDrug

    verducatib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of treatment-emergent adverse events (TEAEs) over the course of this trialTime frame: up to 78 weeks

Locations

394 sites in 41 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • University of Arizona

    Tucson, Arizona

  • Newport Native MD, Inc

    Newport Beach, California

  • Paradigm Clinical Research - Redding

    Redding, California

  • University of California Davis

    Sacramento, California

  • University of California San Francisco

    San Francisco, California

  • National Jewish Health

    Denver, Colorado

  • Meris Clinical Research-Brandon-69466

    Brandon, Florida

  • University of Florida College of Medicine

    Jacksonville, Florida

  • Mayo Clinic - Florida

    Jacksonville, Florida

  • Essence MD Research

    Naples, Florida

  • Vantage Clinical Trials - Tampa

    Tampa, Florida

  • Cleveland Clinic Florida

    Weston, Florida

  • Augusta University

    Augusta, Georgia

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic, Rochester

    Rochester, Minnesota

  • HealthPartners Specialty Center 401 Building

    Saint Paul, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • New York Medical College - Hawthorne

    Hawthorne, New York

  • Northwell Health

    New Hyde Park, New York

  • New York University Langone Medical Center

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • New York Presbyterian Hospital -Columbia University

    New York, New York

  • Stern Research Partners, LLC

    Huntersville, North Carolina

  • Pinehurst Medical Clinic, Inc. - East

    Pinehurst, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Clinical Research Associates of Central PA

    DuBois, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Jefferson Health Honickman Center

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Clinical Research of Rock Hill

    Rock Hill, South Carolina

  • Horizon Clinical Research Group

    Cypress, Texas

  • Baylor University Medical Center

    Dallas, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • El Paso Pulmonary Association

    El Paso, Texas

  • University of Texas Medical Branch at Galveston

    Galveston, Texas

Showing 40 of 394 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.